The purpose of this project to evaluate de novo synthesis of a short polypeptides, which is capable of inhibiting tumor angiogenesis. tumor growth in general and ovarian cancer in particular is associated with angiogenesis, the synthetic peptide can be used to inhibit growth . and peritoneal seeding of ovarian cancer. 14 
INTRODUCTION
The use of agents that can inhibit angiogenesis, particuiarly in anti-tumor research has indicated that anti-angiogenic therapy can be a promising therapeutic modality in the future. Most anti-angiogenic agents have been discovered by identifying endogenous molecules, primarily proteins, that inhibit EC growth. Some of these angiostatic compounds are currently in various phases of clinical cancer trials (http.'//cancertrials.nci.nih.gov). Although a number of compounds have shown promise in the clinic, no major breakthroughs have been reported using anti-angiogenic agents as stand-alone therapy. This underscores the need for more and better angiostatic compounds for use as stand-alone treatment or in combination with conventional therapies.
Recently, we reported the design of the anginex peptide (also know as 6pep25), a cytokine-like B-sheet-forming peptide 33mer, which is a potent inhibitor of angiogenesis and tumor growth. Anginex is more effective at inhibiting EC growth than platelet factor-4 and several other well-known angiogenesis inhibitors such as angiostatin, endostatin, AGM-1470 and thrombospondin-1.
BODY
Hypothesis: Anginex (Bpep25) and its designed analogs can be used to abrogate tumor growth in vivo and potentiate the action of chemotherapy or radiation, making use of lower, less toxic, doses of either conventional modalities.
The objectives are to perform in vitro and tumor model studies in mice using MAI 48 ovarian cancer cell line in the absence and presence of either chemo¬ therapeutic agents or radiation. Studies will be performed to elucidate the essential amino acids of the peptide and by modifying the amino acid sequence, its own efficacy will by tried to be improved. Given the angiostatic potential of anginex and its analogs, the overall aim of this research is to develop anginex or an analog into an anti-tumor therapeutic agent against ovarian cancer.
Relevance to Ovarian Cancer: The tumor model studies mentioned above will be performed using an ovarian cancer cell line, MAI 48. In this regard, studies will be performed to specifically assess the efficacy of treatment of the peptide and its analogs on ovarian carcinoma.
Metholoav and Design:
Specific Aim 1: define structure-activity relationships in anginex and design new, more potent Bpep sequences. The Bpep-25 (anginex) sequence will be modified by substituting individual amino acid residues and by analine scanning. Walkthrough peptides will also be generated. Peptides will then be screened for various in vitro bioactivities relating to angiostatic potential: endothelial cell (EC) proliferation and collagen gel based tube formation assay. Proper folding of peptides will be assessed by using CD and NMR in order to 3 differentiate direct and indirect (conformational) effects. The initial round of amino acid substitutions will naturally lead into multiple substitutions and designing in conformational constraints (rationally placed S-S bond(s) or specific turn sequences). Designing and bioassying will be applied iteratively with the intent of improving angiostatic potential. Results for Aim 1 in year 4: Already in the first 3 years, alanine scanning and walkthrough Bpep-25 peptides were synthesized and analyzed in in vitro assays, and structure-function relationships were derived. After identifying the key residues for the activity, all lying on the same surface of the folded peptide, a series of partly non-peptidic mimetics were designed. This series uses a dibenzofuran (DBF) scaffold onto which are covalently attached short, key amino acid sequences derived from anginex. Recently, we provide evidence that Bsheet is in fact the bioactive conformation of anginex, by using a series of double-cysteine disulfide-bridged analogs CD and NMR spectral analysis of the analogs indicate formation of B-sheet conformation. As long as placement of disulfide bonds preserved the B-strand alignment as in the proposed bioactive conformation, bioactivities were preserved. Specific Aim 2: elucidate the molar mechanism of action of anginex by which angiostatic effects are mediated. This includes identifying the angiostatic pathway, the receptor(s) involved, and the internalization pathway. Results for Aim 2 in year 4: From former years, we knew that essentials of the molecular mechanism of anti-angiogenic action of anginex. The peptide interacts with a receptor, CD36, on the surface of EC, becomes internalized and triggers the apoptotic cascade. This process is specific for angiogenically-activated EC where CD36 is upregulated, and does not affect resting EC or other cell types. This year, we discovered that anginex may also be interacting with a2-integrins. The peptides analogs, although highly cytostatic, do not induce apoptosis applying the same mechanism as anginex. A clear understanding of the molecular mechanism of either anginex or its analogs is still in its infancy. Specific Aim 3: study effectively to Inhibit angiogenesis and tumor growth in vivo. For this aim, we have focussed on performing nude mouse tumor growth models. In these studies, the ovarian cancer cell line MA148 will be used. In these models, all pre-cinical research can be performed to prepare the research line for phase I clinical trials. Pharmacokinetics and tissue distribution of peptides in animals will then be studied with the use of anti-peptide mAbs, polyclonals and mass spectrometry. Results for Aim 3 In year 4: The ovarian cancer cell line MA148 has been used in nude mice tumor studies with anginex and its analogs. For these studies, MAI 48 cancer cells have been injected SC into the hind flank of nude mice and turners have been allowed to establish prior to administrating the drug. At the optimal dose 10 mg/kg over a 4-week period, tumor size was reduced by about 70®/o, somewhat greater than that of angiostatin (well-know angiogenesis inhibitor). In this model, one of the analogs, 6DBF7 (also known as CF8) functioned better than parent peptide anginex by reducing tumor volume to about 90% at the same dose. Apparently, this novel design, holding on to the bioactive conformation (B-sheet), improved the bioavailablity of the pharmaceutic. Specific Aim 4: investigate combined angiogenesis and chemotherapy in vivo. Additional studies will be performed to investigate whether conventional chemotherapy can be improved by co-administration with anti-angiogenic Bpep peptides. Results for Aim 4 In year 4: Using the ovarian cancer mouse model (MAMS) as described above, we were able to show that when anginex (10 mg/kg) was combined with a sub-optimal dose of carboplatin (32.5 mg/kg), tumors regressed to art impalpable state in all the mice. Carboplatin was chosen because it is the leading chemotherapeutic against ovarian carcinoma used in humans. However, these tumors remained undetectable until at least one week after termination of the treatment, after which tumors re-established themselves, indicating continued presence of microscopic disease, which was unresponsive to carboplatin and apparently independent of angiogenesis. In different experiments using the same set-up we combined anginex with chemotherapeutic paclitaxel which not resulted in a syriergistic effect when the treatments were combined. Presently we are combining anginex (10 mg/kg) in the ovarian mouse model with a sub-optimal dose of radiation (5 Gy once a week), and tumors regressed to an impalpable state similar to the combination of anginex and carboplatin. Using a syngeneic breast tumor mouse model anginex inhibited the carcinoma growth by about 40% as monotherapy and the combination of anginex with radiation (single dose of 25 Gy) resulted in a significant improvement in survival and complete responses In 60% of the mice.
KEY RESEARCH ACCOMPLISHMENTS -anginex inhibits the growth of ovarian cancer by about 70% -using information derived from structural activity assays, functional key residues were identified. In addition, we identified that B-strand alignment is the bioactive conformation, which was applied in the design of the series of partial non-peptide mimetics. The most efficacious of these analogs is 6DF7. -6DBF7 inhibits the growth of ovarian tumors in athymic mice by about 90%, an improvement over anginex. -when anginex treatment is combined with a sub-optimal dose of carboplatin or radiation in the ovarian mouse model complete tumor regressions are noticeable.
INTRODUCTION
Angiogenesis, the formation of new blood vessels out of pre¬ existing capillaries, is pivotal to a broad array of biological functions, ranging from normal processes like embryogenesis and wound healing to abnormal processes such as tumour growth, arthritis, restenosis and diabetic retinopathy [1, 2] . Hie use of agents that can inhibit angiogenesis in vitro and in vivo, particularly in anti-tumour research, has indicated that anti-angiogenic therapy can be a therapeutic modality in the future. Most anti-angiogenic agents have been discovered by identifying endogenous molecules, primarily proteins, which inhibit endothelial cell (EC) growth. This traditional approach has produced a number of anti-angiogenics, such as platelet factor-4 (PF4) [3] , thrombospondin-1 [4] , angiostatin [5] , endostatin [6] and bactericidal-permeability increasing (BPI) protein [7] . Recently, we have reported [8, 9] the anti-angiogenic activity of a novel peptide 33mer ()Spep-25 or anginex). Anginex belongs to a family of homologous ^pep peptides that were designed by using basic folding principles and incorporating short sequences from the fi-shcei domains of a-chemokines and BPI protein [10] . All ^pep peptides form -sheets to varying degrees and can self¬ associate in solution as dimers and tetramers [9, 10] . A highresolution NMR structure of tetrameric j0pep-4 demonstrated that its monomer subunits are folded into an amphipathic three-stranded anti-parallel y3-sheet motif [11] . Two types of six-stranded anti-parallel ^-sheet dimers can form and these dimers associate via their hydrophobic faces into tetramers. Although a high-resolution structure of anginex (j6pep-25) could not be determined by using NMR because of aggregate exchange resonance broadening, CD and NMR studies [8, 9] indicate that anginex also folds primarily into tetrameric ^-sheet sandwiches at millimolar concentrations. At concentrations in the micromolar range and lower, however, anginex exists in solution primarily in the monomer state and is composed of a relatively broad distribution of conformations with considerable random coil and some ^-sheet character [12] . Therefore, at the micromolar concentrations used in in vitro bioassays and in vivo animal studies demonstrating the anti-angiogenic [8, 9] and anti-tumour [13] [14] [15] potency of the peptide, anginex is mostly a random coil monomer. Therefore the bioactive structure of anginex, which is selected from this rather broad conformational distribution, remains unclear.
The aim of the present study was to test the hypothesis that the bioactive conformation of anginex (/9pep-25) is a ^-sheet with the same strand alignment as in the NMR-deiived structure of homologous ^pep-4 (see Figure 1 ) [11] . To accomplish this, a series of disulphide-linked peptide analogues of anginex were made. By comparing activities from all 30 members of the ^pep library, it has already been deduced [9] that functionally key residues in anginex are primaiily hydrophobic residues, i.e. Leu^, Val', Ile^, Val^^ and Leu^. Because of this, cysteine residues replaced residues primarily at positions that would be on the hydrophilic face of the ampWpatMc anginex ^-sheet. Moreover, to simplify peptide synthesis and purification, six functionally nonessential residues at the C-terminus of anginex [9] were removed, creating a peptide 27mer analogue of anginex that is shown in the present study to be equipotent with the parent peptide. Double-substituted cysteine pairs were made: Cys®-Cys^, Cys*-Cys^, Cys*«-Cys"\ Cys'2-€ys*^ Cys''-Cys'», Cys*^-€ys'" and Cys®-Cys^®. These disulphide-bridged analogues were analysed in three functional assays: EC proliferation, apoptosis and in vitro Abbreviations used: BPI protein, bactericidal-permeability increasing protein; bFGF, basic fibroblast growth factor; CP, cyclicized peptide; EC, endothelial cell; HUVEC, human umbilical-vein EC; NOE, nuclear Overhauser effect; PF4, platelet factor-4; PFG, pulsed-field gradient; PI. propidium iodide-RMS root mean square.
^ To whom correspondence should be addressed (e-mail mayox001@umn.edu).
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EXPERIMENTAL Peptide preparation
Peptides were synthesized using fluoren-9-ylmethoxycarbonyl ('Fmoc') chemistry on a Milligen/Biosearch 9600 peptide solidphase synthesizer, as described previously [8, 9] . To form intramolecular disulphide bonds, crude peptides were solubilized at low concentrations (100 fiM) and cysteine residues were oxidized by slowly bubbling wet oxygen gas into a stirred aqueous solution overnight at room temperature. Freeze-dried crude peptides (oxidized) were purified by preparative reversephase HPLC on a Cl 8 column with an elution gradient of 0-60% (v/v) acetonitrile with 0.1 % (v/v) trifluoroacetic acid in water. Purity and composition of the peptides were verified by HPLC (Beckman Model 6300), amino acid analysis and MS. The presence of the disulphide bond was checked in all peptides by using 5,5'-dithiobis-(2-nitrobenzoic acid (Eilman's reagent; 'DTNB') pre-and post-treatment with dithiothreitol.
CD
Aqueous solutions for CD were prepared by dissolving the freeze-dried peptide in the appropriate amount of water to give final peptide concentrations of 0.1 mM at pH 5.5. Concentrations were verified by tryptophan absorption at 280 nm. CD spectra were recorded on a Jasco J-710 spectrophotometer using either a 0.01 cm or 0.1 cm path-length thermally jacketed quartz cuvette maintained at 24 or 37 °C with a NesLab water bath. Acquisition was performed using a 50 nm/min scan rate, 1 nm bandwidth and 2 s response. The appropriate baseline was subtracted from each spectrum. Reported spectra are averages of six scans and are expressed as mean residue ellipticity. CD basis spectra (a-helix, ^-sheet and random coil) were measured with poly(lysine) and poly(giutamic acid) (Sigma) using conditions and parameters reported previously [16, 17] . Experimental CD spectra were fitted with a linear combination of a-helix, fi-shcet and random coil basis spectra to estimate secondary structure contributions.
NMR measurements
For NMR measurements, the freeze-dried peptide was dissolved in water at a concentration of approx. 2 mM. The pH was adjusted to pH 5.5 by adding microlitre quantities of NaOH or HCl to the peptide sample. NMR spectra were acquired on a Varian UNITY Plus-600 NMR spectrometer using a homonuclear approach described previously [8] . Data were processed directly on the spectrometer or offline using VNMR (Varian, Inc., Palo Alto, CA, U.S.A.) or NMRPipe [18] on an SGI workstation and were analysed using Sparky (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, San Francisco, CA, U.S.A.). Since cyclicized peptides (CPs) are relatively hydrophobic and amphipathic, pulsed-field gradient (PFG)-NMR self-diffusion measurements were performed as a check for peptide aggregation. PFG-NMR experiments were performed and analysed as described by Mayo et al. [10] using a Varian Unity-Plus 500 NMR spectrometer. The maximum magnitude of the gradient was 60 G/cm, and the PFG longitudinal eddy-current delay pulse sequence was used for all self-diffusion measurements which were performed in ^H20 at temperatures of 5 °C and 40 °C. Peptide concentrations ranged from 0.1-2 mM.
Structural modelling
Analysis of nuclear Overhauser effect (NOE) data and structural modelling (using X-PLOR [19] ) were performed essentially as described previously [20] . Calculated structures were superimposed using the SwissPdbViewer [21] or Insight II (Accehys, Inc., San Diego, CA, U.S.A.) and were analysed using X-PLOR analysis routines.
Human umblllcal-vein EC (HUVEC) cultures 
Apoptosis measurement
HUVECs were cultured in fibronectin-coated tissue-culture flasks in culture medium [22] . Apoptosis was measured by determination of subdiploid cells after DNA extraction and subsequent staining with propidium iodide (PI) as described previously [23] . Briefly, HUVECs were cultured for 3 days in the presence of 10 ng/ml basic fibroblast growth factor (bFGF) and the conditions as mentioned above. Serum deprivation of HUVECs was used as a positive control for apoptosis. Cells were then harvested and subsequently fixed and permeabilized in 70 % (v/v) ethanol at ~ 20 °C. After at least 2 h, the cells were centrifuged and resuspended in DNA extraction buffer [45 mM Na2HP04, 2.5 mM citric acid and 0.1 % Triton X-KK) (pH 7. 
In vitro angiogenesis assay
Sprouting and tube formation of bovine ECs were studied using Cytodex-3 beads overgrown with bovine ECs in a three-dimensional collagen gel (vitrogen-100; Collagen Corp., Fremont, CA, U.S.A.) as described by van der Schaft et al. [24] , Following gelation, culture medium containing 20 ng/ml bFGF, with or without anginex or CP analogues, was applied on top of the gel. Photographs were taken after 24 h of cell culture at 37 °C. Sprouts were traced on transparent paper and digitized by scanning using HPscan software. Analysis of the amount of sprouting was performed by binarization of the file and ji3-Sheet bioactive conformation for anginex quantification of sprout pixel count using Scion Image software, which yields a measure of sprout length [25] .
RESULTS AND DISCUSSION
For the CP series, all CP analogues have the same sequence as anginex minus the six C-terminal residues Arg-Glu-Leu-SerLeu-Asp ( Figure 1 ). CP-1 is the control linear peptide 27mer (no cysteine residues), and CP-2 to CP-8 are double-cysteinesubstituted disulphide-bridged peptides: Cys®-Cys^ (CP-2), Cys«-Cys2^ (CP-3), Cys^^-Cys^' (CP-4), Cys'^^ys^^ (CP-5), Cys*3-Cys'' (CP-6). Cys'^-Gys*^ (CP-7) and Cys^-Cys^® (CP-8).
The amino acid sequences for parent anginex and CP-1 are given in Figure 1 , and positions for disulphide bonds in CP-2 to CP-6 are indicated by curved lines at the right of the CP-1 sequence. Because functionally key residues in anginex are primarily hydrophobic, i.e. Leu^ Val^, Ile^®, Val^ and Leu^, and would lie on one side of the amphipathic structure in a -sheet conformation [9] , residues on the hydrophilic face (and not the hydrophobic face) of the proposed ^-sheet were substituted with cysteine residues. For assurance that cysteine-substituted positions did not affect activity of the parent peptide, single-substituted alanine variants (Ser^ -> Ala, Gin* Ala, Lys*® -> Ala, Phe*^ Ala, Lys*^ Ala, Trp'* Ala, Lys*^ Ala, Ile^^ Ala, Lys^ Ala, Asn^ Ala and Asp^^ Ala) were also made and tested in the in vitro EC proliferation assay. Relative to the parent peptide, activities were unaffected solely by amino acid substitutions at these positions (results not shown). On forming an actual ^-sheet in CP-2 to CP-6, positioning of disulphide bonds constrains the -strand alignment to be die same as that proposed for the folding of anginex [8] . 
CD
CD and NMR spectroscopies were used to assess the con¬ formation of CP analogues. For all CP analogues, far-UV CD traces indicated a mixture of ^6-sheet and random coil conformations (Figure 2) , with the degree of ^-sheet character corresponding to the intensity of the characteristic 217 nm trough [17, 26, 27] . Linear combinations of secondary structure basis spectra (a-hehx, -sheet and random coil) fitted to the CP analogue spectra (Figure 2, inset) showed the largest ^-sheet content (79 %) in the linear CP-1 peptide and the smallest (40%) in CP-6. Fitted data indicate the absence of helical content for most of the CP analogues. Even though CP-4, CP-5 and CP-6 show 2-6% helix content, this contribution is small enough that it is within the error from the fitting process. In addition, because the CP analogues are relatively flexible, the secondary structure contributions are only meant to semi-quantify the trend in )3-sheet content. Nevertheless, the CP analogue conformational distributions are consistent with that for anginex [11] .
NMR conformational analysis
Even though CD data demonstrate the presence of significant populations of )5-sheets in aU CP analogues, proton NMR spectra for all CP analogues, except CP-2, are characteristic of mostly random coil conformations (results not shown). CP-2 is the only CP analogue that shows well-dispersed resonances indicative of a well-folded structure [28, 29] . Since the parent anginex peptide exists in solution in a monomer/dimer/tetramer equilibrium [29, 30] , PFG-NMR self-diffusion measurements were performed on CP analogues (results not shown). Analysis of the CP analogue difriisivities indicates that, at a concentration of 2 mM, CP-2 is mostly dimeric, whereas the other CP analogues are a mixture 284 R. R M. Dings and others Several cross-peaks have been labelled to indicate Intra-and inter-monomer aH-aH NOEs, which have been used to Indicate ^-strand alignment. In (B). the cross-peaks are labelled with two numbers separated by a solidus to Indicate which residues in the sequence are involved. Single-letter amino-acid notation has been used. of dimers and monomers. None of the CP analogues apparently associates with the tetramer state like anginex.
NMR structure of CP-2
Because initial NMR experiments indicated that CP-2 is wellfolded, a complete NMR structure analysis of this peptide was performed. The orH-NH region of a TOCSY plot of CP-2 shows high frequency dispersion of NH and aH resonances, indicating the presence of a well-folded y8-sheet conformation ( Figure 3A ). This is also evident by the observation of cross-strand aH-aH NOEs ( Figure 3B and Figure 4A ). Structurally, these NOESY data indicate the presence of the same anti-parallel ^-sheet strand alignment as observed in )6pep-4 and other ^pep peptides [11] .
For CP-2, conformational modelling was performed using NOE data acquired for the peptide, A total of 160 NOE distance constraints were derived from analysis of NOESY spectra. These include 94 intra-residue, 22 sequential, 16 medium-range (If -j\ < 5) and 28 long-range (li -yl > 5) constraints. In addition, a total of eight hydrogen bonds were identified by inspection of initial CP-2 structures and from long-lived backbone NHs, giving rise to 16 hydrogen bond distance constraints. The total number of experimentally derived constraints was therefore 168, giving an average of six constraints/residue. Initially, 100 structures for CP-2 were calculated as described in ie Experimental section. The best-fit superpositions of backbone Ca atoms for the final 18 structures are shown in Figure 4 (B). These structures showed no NOE violations greater than 0.5 A (where 1 A = 0.1 nm). Structural statistics (Table 1) show that the Nterminus is somewhat less structurally defined and that the Even though only CP-2 is well-folded as an anti-parallel sheet, it is most probable that peptides CP-3, CP-4, CP-5 and CP-6 share the same overall -sheet fold, because they only differ in the position of the disulphide bridge.
CP analogues inhibit EC proliferation CP analogues were tested for their ability to inhibit the proliferation of growth-factor-induced (bFGF, lOng/ml) HUVECs in the pH]thymidine incorporation assay [15] . Relative to the activity of the parent peptide anginex [8] , CP analogues effectively iiihibited the proliferation of HUVECs to various extents ( Figure 5 ). Although the linear control, CP-1, and three of the disulphide-bridged variants, CP-4, CP-5 and CP-6, were essentially as effective as anginex, CP-2 and CP-3 appeared to be almost as active, and control peptides CP-7 and CP-8 were only slightly active. The kinetics of these anti-proliferative effects on ECs were similar to those found for anginex, with half-maximal effects after 36-40 h and maximal responses after 3 days. As with anginex, the inhibition of proliferation by CP analogues was specific for ECs, since proliferation of fibroblasts obtained from human endometrium was unaffected (results not shown).
CP analogues promote apoptosis in ECs
To investigate whether CP-induced inhibition of EC growth is based on specific induction of apoptosis in these cells, as was demonstrated for anginex [8] , HUVECs were exposed to 25 /xM peptide for 48 h, and the percentage of cells undergoing apoptosis was quantified by analysis of DNA fragmentation following DNA extraction, PI staining and flow cytometric analysis. Although all CP analogues demonstrated apoptotic activity, CP-4 and CP-5 were the most active and even slightly more effective, on average. than anginex ( Figure 6A ). Since apoptosis in this assay is defined as those subdiploid cells with a minimum of 10% of the DNA content of the diploid cells, advanced or late stage apoptosis may result in less than 10% of that value. Consequently, the total number of dead cells was also quantified ( Figure 6B ). The loss of ECs in Ga and M {4n DNA) phases of the cell cycle is approx, 10% or less (results not shown). The correlation between apoptosis induction and anti-proliferative effects suggests that CP analogues, like anginex, regulate EC growth by forcing ECs to undergo apoptosis.
In vitro angiogenesis assay
Since angiogenesis is a complex process, which, aside from EC proliferation, depends on cell migration and differentiation, the /S-Sheet bioactive conformation for anginex 287 effects of CP analogues on angiogenesis were investigated in an in vitro collagen matrix-based sprout formation assay [13] [14] [15] . Although all CP analogues were able to inhibit sprout formation to various extents, the best responses, comparable with those from anginex, were observed with CP-1 and CP-2. It was somewhat surprising that CP-4, CP-5 and CP-6, which were the most effective at inhibiting EC proliferation, were not as effective in this assay. One reason for this could be the complexity of the collagen gel sprouting assay itself. Because these peptides must first navigate through the gel before exerting their effect on ECs, it may be that CP-1 and CP-2 permeate the gel better than other CP analogues or interact somewhat differently with the gel matrix. Alternatively, it may be that the sprouting assay is indeed the more sensitive indicator of anti-angiogenic potential. In any event, bioactivity in this angiogenesis assay decreased most when the -strand alignment was shifted, as in CP-7 and CP-8, indicating that that specific strand alignment is crucial to maintaining full bioactivity.
Conclusions
In the present study, we demonstrate that the bioactive conformation of the anti-angiogenic anginex peptide is an anti¬ parallel j6-sheet. This finding is consistent with earlier results [8, 9] on anginex that in the ^-sheet conformation all five hydrophobic residues (Leu^, Va'^ Ile^, Val^^ and Leu^), which were identified as being crucial to anti-proliferative activity, are proximal and are conformed on the hydrophobic face of the amphipathic ^-sheet [9] . Comparison of the three-dimensional structures of several anti-angiogenic proteins, e.g. endostatin [31] , PF4 [32] , tumour necrosis factor [33] and BPI protein [34] , provides a higher level of structural commonality among anti-angiogenic proteins in that they are comprised primarily of anti-parallel ^-sheet structure. Furthermore, a survey of amino acid sequences from numerous anti-angiogenic proteins reveals that they are compositionally similar, containing numerous hydrophobic and cationic residues. These structural and compositional characteristics, which appear to be functionally important, are embodied in anginex [9] . As structure-function relationships in these and other antiangiogenic proteins and peptides become known, it will be interesting to see if this is a common feature among antiangiogenic proteins. Knowing that this ^-sheet conformation is that which promotes anti-angiogenic activity will aid in the development of small molecule mimetics of the anginex peptide.
Introduction
Although it was hypothesized some 30 years ago that inhibition of angiogenesis could attenuate tumor growth [1, 2] , it was only after the isolation, identification and in vivo testing of the angiogenic inhibitory protein frag¬ ments angiostatin [3] and endostatin [4] that Folkman's hypothesis gained general acceptance. Since that time, numerous angiogenesis inhibitors (over 300) have been identified, a number of which are currently in various phases of htiman cancer trials (http;//cancertrials.nci.nih.gov). Even though a few anti-angiogenic compounds have demonstrated promise in the clinic, no major clinical breakthroughs have been reported using a stand-alone anti-angiogenic agent as a thera¬ peutic, and even some of these compounds have failed in clinical testing (e.g. SU5416, BB2516, AG3340, Bay 12-9566, IM-862 [5] ). This underscores the need to identify and develop more and better angiogenesis inhibitors and to perform clinical studies with them either as mono¬ therapy or in combination with conventional treatment strategies.
Tumor angiogenesis is a highly complex biological process, and blocking only one step of this process may merely force a growing tumor to circumvent the particular blocked pathway. Tumors have in their arsenal a number of ways to promote angiogenesis, and anti-angiogenics can inhibit neovascularization at different steps in the formation of new blood vessels. For example, agents that block specific angiogenic ligands, e.g. VEGF, or their receptor-mediated signaling pathway(s) only block one of the angiogenic factors secreted by tumors, leaving open the possibility that a tumor can adapt and switch angiogenic stimulators, e.g. from VEGF to FGF, in a second wave of VEGFindependent angiogenesis [6] .
The complexity of tumor-induced angiogenesis also rests in the micro-environment of a given tumor, which further complicates development of a highly effective anti-angiogenic agent. For example, hypoxia and isch¬ emia trigger the production of angiogenic survival factors, such as VEGF, but also of endothelial apopto¬ sis-inducing factors like TNF-a [7, 8] . The level of production of these factors is important because some cytokines, such as TNFa and TNFj5, can function both as stimulators and inhibitors of angiogenesis depending upon their concentration. Another example is thrombospondin-2 (TSP-2), which displays anti-angiogenic activity [9, 10] , via secretion from fibroblasts, and possibly other mesenchymal cells, as a paracrine medi¬ ator of EC proliferation [11] . Such agents are therefore contextual inhibitors of angiogenesis that depend on their presence within a particular physiological environ¬ ment.
Angiogenesis inhibitors have been identified using a myriad of approaches, including (1) isolation and identification of endogenous inhibitors of tumor-pro¬ moted angiogenesis [4] , (2) gene therapies [12] , (3) antibody therapies against pro-angiogenic molecules [ [15] , (6) soluble growth factor receptors as antagonists [16] , (7) interference with growth factor signaling [17] , (8) ribozymes [18] , (9) small molecule inhibitors [19] , and (10) peptide design [20] .
Angiogenesis inhibitors, particularly those specific for endothelial cells (ECs), are now also being used as 'homing'-devices for chemotherapeutics in the hope of increasing specificity and reducing toxicity. The tumor¬ homing capacity of EC-specific peptides was successfully used to target doxorubicin, a frequently used chemo¬ therapeutic with intrinsic anti-angiogenic activity [21] . In xenograft models, this targeting approach resulted in prolonged survival, reduction of the optimal effective dose and reduced toxicity. Targeting can be done either classically by linking the chemotherapeutic chemically to the anti-angiogenic compound or in a novel approach by linking it to peptides which specifically target tumor vasculature [22] .
The most promising anti-angiogenics are those that act directly on ECs to inhibit tumor angiogenesis, an approach that is less prone to drug resistance and can be more therapeutically effective against a broad spectrum of tiunors. The well-known proteins, angiostatin and endostatin, are two such EC-specific angiogenesis in¬ hibitors. Although there are nximerous proteins known to be anti-angiogenic, this review is focused on the discovery and/or development of protein fragments and small peptide inhibitors of angiogenesis. Moreover, this treatise is not meant to be exhaustive; rather it is an attempt to review this literature with a slant towards better understanding structural similarities and struc¬ ture-function relationships through this general class of anti-angiogenic agents.
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elastase cleaves plasminogen into an active form of angiostatin in vitro, it is not yet clear which protease(s) is (are) involved in the conversion of plasminogen to angiostatin in vivo. However, it was recently suggested that depending on the type of tumor, either tumor cells themselves or tumor-associated macrophages express enzymatic activity capable of converting inactive plasmi¬ nogen into angiostatin. Although plasminogen itself does not bind to the integrin receptor it appears that angiostatin does, suggesting that interaction with oCyp^ is, in part, responsible for the anti-angiogenic properties of angiostatin [24] . At least two other possible receptors for angiostatin have been reported: ATPsynthase [25] and integrin oc^pi [24] . Table 1 lists receptors reported for angiostatin and other anti-angiogenic protein fragments and peptides.
Other proteolytic fragments of human plasminogen can also inhibit neovascularization and growth of lung metastases in mice [3] . For example, kringle 1 (Kl) potently inhibits EC growth, whereas K4 exhibits almost no anti-angiogenic activity in vitro [23] . Interestingly, K5, which is not present in angiostatin, is structurally related to the other four kringles in plasminogen and also exhibits anti-endothehal activity [26] .
The crystal structure of three kringles from angiost¬ atin [27] folds, as expected for a kringle-structured protein, into anti-parallel ^-sheet and aperiodic loops. These three kringles are organized in an overall L-shape. Because angiostatin contains a nearly equal number of anionic and cationic residues, the surface of the folded protein is relatively neutral. Nonetheless, the most outstanding electrostatic feature of the protein is a highly electropositive lysine-rich binding site. This is a
Protein fragments
One approach that has been used to identify molecules with anti-angiogenic potential is to isolate components from the serum or body fluids of animals undergoing extensive angiogenesis, i.e., tumor-bearing or pregnant animals. Many, if not most, of these components were found to be fragments of proteins, which, relative to their parent protein that may or may not be antiangiogenic by themselves, display anti-angiogenic prop¬ erties when separated from their parent protein. Al¬ though endostatin and angiostatin are perhaps the best known examples of such protein fragments, others are discussed below as well.
Angiostatin
The circulating angiogenesis inhibitor angiostatin [3] is a fragment of the non-anti-angiogenic plasma protein plasminogen. Angiostatin contains the first four triple¬ loop disulfide-linked regions of plasminogen, known as kringle domains [3, 23] . This approximately 40 kDa protein was initially isolated from the serum and urine of mice with Lewis lung carcinoma (LLC). Although Angiostatic proteins and peptides recurring structural/compositional theme for most antiangiogenic proteins and peptides identified so far: antiparallel jS-sheet structure and proponderance of positively charged and hydrophobic residues.
Endostatin
Endostatin was discovered using a similar approach as with angiostatin, albeit with hemangioendothelioma as the tumor source [4] . Like angiostatin, endostatin specifically inhibits proliferation of EC in vitro and tumor growth in various mouse models in vivo. Fur¬ thermore, endostatin has been shown to induce EC apoptosis in the presence of minimal serum. Endostatin is a 20 kDa C-terminal proteolytic fragment of the NCI domain of collagen XVIII, which is a member of a family of collagen-like proteins referred to as multiplexins and is localized primarily in the extracellular matrix surrounding blood vessels. The multiplexin family of collagens is distinguished by nearly 60% sequence identity within the final 184 residues of their C-terminal globular domains [28] , suggesting that any one of these fragments likewise would be anti-angiogenic. This was recently confirmed by the anti-angiogenic activity of restin, the C-terminal non-coUagenous region (NCIO) of the al chain of human type XV collagen [29] .
The precise mechanism of action for endostatin remains elusive, primarily because endostatin has been found to interact with multiple 'receptors' (Table 1) . Endostatin is known to associate with integrin as^i, to anchor protein caveolin-1, and to activate Src via a tyrosyl phosphatase-dependent pathway in human ECs [30] . These are in addition to earlier reports that endostatin contains a ROD (Arg-Gly-Asp) sequence and binds to integrins and [31] , Furthermore, endostatin, as well as angiostatin, increase cytoplasmic Ca^'*' in ECs immediately following exposure [32] .
The crystal structure of endostatin [33] shows the amino acid sequence to be folded into predominantly anti-parallel ^-sheet structure, with interspersed extend¬ ed loops and two short a-helices, as illustrated in Figure lA . The structure of endostatin is homologous to that of E-selectin [34] . In fact, the entire y?-sheet structure of E-selectin is contained within the endostatin structure. Endostatin is highly positively charged, par¬ ticularly due to the presence of multiple arginine residues and has a high affinity for heparin, which is required for the full activity of the peptide [35] .
Tumstatin and tum-5
Recently, the C-terminal globular non-collagenous NCI domain of the a3 chain of human type IV collagen (a3(IV)NCl) called tumstatin [36] , was reported to have anti-angiogenic properties [37] . Aside from its ability to inhibit angiogenesis in vitro and in vivo, tumstatin also inhibits tumor cell proliferation [37, 38] . Using deletion mutagenesis, Maeshima et al. [37] found that the antiangiogenic activity of tumstatin appears to be localized between amino acid residues 54 and 132, a fragment named tum-5, whereas its tumor proliferation inhibitory activity resides between amino acid residues 181 and 244. Maeshima et al. also demonstrated that both tumstatin and tum-5 bind to (Table 1) in an RGD-independent manner and that binding is pivotal for anti-angiogenic activity [39] . In vivo studies demon¬ strate that at a molar-equivalent concentration, human tum-5 is at least 10 times more active than human endostatin [40] .
PEX
The non-catalytic C-terminal haemopexin-like domain (PEX) of the matrix metalloproteinase MMP-2 can interact with integrin to block MMP-2 binding and thereby inhibit angiogenesis. MMPs are mosaic proteins containing an N-terminal pro-domain, a catalytic Zn^"^ protease domain and the C-terminal PEX haemopexinlike domain. PEX2 appears to be a naturally occurring breakdown product of MMP-2. This protein fragment can inhibit cell-associated collagenolytic activity with preferential substrate specificity towards type IV colla¬ gen, which is thought to play an important role in EC proliferation and behaviour during the angiogenic process because it is a major macromolecular constitu¬ ent of basement membranes [41] . Consequently, PEX inhibits angiogenesis and, in this way, controls normal angiogenesis and neovascularization. Since MMP-2 does not contain the RGD sequence, PEX binding to cCyP^ (Table 1) is RGD-independent. Therefore, exoge¬ nously administered PEX may be a therapeutic inhibitor of diseases associated with angiogenesis [42] and may be less toxic than treatment with MMP enzyme inhibitors themselves [43] .
The structure of the PEX domain in MMP9 is a noncovalent asymmetric homodimer, consisting of multiple j?-sheets. The overall structure of PEX9 adopts a fourbladed y?-propeller, and blade IV of PEX9 mediates the non-covalent and predominantly hydrophobic dimer¬ ization contact [44] ,
Anastellin
Anastellin is another anti-angiogenic peptide (76 amino acid residues), derived from the first type III repeat of fibronectin [45] , which contains a site important in fibronectin self-assembly into fibrils [46] . Anastellin may disrupt intermolecular interactions that maintain fibro¬ nectin in its soluble form [46] , and this disruption may induce the molecule to undergo assembly into fibrils [45] . Alternatively, anastellin may change the confor¬ mation of fibronectin in such a way that cryptic fibronectin-fibronectin binding sites that are capable of driving fibril assembly are exposed. Systemic treat¬ ment of tumor-bearing mice with anastellin suppresses the growth of subcutaneous tumors and inhibits tumor angiogenesis, as well as metastasis [47] .
This first type III repeat in fibronectin has a similar function as the NCI domain from collagen IV. This suggests a common mechanism for anti-angiogenic substances derived from extracellular matrix and blood proteins [47] , especially considering that these antiangiogenic substances bind to adhesion molecules con¬ taining the RGD-sequence. For instance, angiostatin binds to vitronectin, endostatin binds to fibulins, and nidogen-2 and anastellin bind to fibronectin and fibri¬ nogen in serum [47] . But moreover, all bind to avft (Table 1) , which is expressed at high levels in angiogenic ECs [48] .
As shown in Figure IB , the fibronectin type III domain consists of seven )8-strands folded into two anti-parallel ^-sheets having an immunoglobulin-like fold similar to that found in homologous modules in the cytokine receptor superfamily [49, 50] . Moreover, the surface of this molecule is highly positively charged.
Others
Prolactin, growth hormone and placental lactogen are members of a family of polypeptide hormones that share structural similarities and biological activities. They modulate angiogenesis along with two non-classical members of the family, proliferin and proliferin related protein. Opposing actions have been described between these two similar, yet independent, molecules (proliferin and proliferin related protein), which can stimulate and inhibit angiogenesis, respectively. The potential to exert R.P.M, Dings et ah opposing effects on angiogenesis can also reside within the same molecule as the parent protein promotes angiogenesis (i.e., prolactin, growth hormone and plac¬ ental lactogen), but after proteolytic processing, the resulting peptide fragment acquires anti-angiogenic properties (i.e,, 16 kDa prolactin, 16 kDa growth hor¬ mone and 16 kDa placental lactogen) [51] [52] [53] [54] , ECs are known to produce various forms of laminin, but the structural characteristics and biological features are incompletely known [55] . Whereas laminin itself, as well as peptides derived from it, are pro-angiogenic [56, 57] , vasostatin (residues 1-180 of the NH2 domain of calreticulin) can bind to laminin, thus promoting antiangiogenic activity. Calreticulin by itself is anti-angiogenic as well [55] . Domain IVa of the laminin a5 chain is likely to be responsible for the angiogenic response of laminin. This domain promotes cell adhesion and binds to pi and otvPs integrins via the RGD sequence [58] . In addition, the laminin receptor 67LR plays an important role in metastasis, tumor invasiveness and tumor angio¬ genesis because it is upregulated during these conditions. Interestingly, the RDGSYGIV peptide derived from epidermal growth hormone (residues 33-42), which inhibits EC motility, is an antagonist for 67LR [59] .
Lastly, the metal-binding glycoprotein osteonectin (also called BM-40 or SPARC) has a protruding Nterminal jS-hairpin with striking similarities to epidermal growth factor (EGF) [60] , Although the molecular structure of osteonectin consists mostly of helices, this j5-hairpin structure is believed to be the site that promotes anti-angiogenic activity.
Small peptides (<50 amino acid residues)
Identification of anti-angiogenic fragments of proteins that are themselves anti-angiogenic, prompted the search for even smaller anti-angiogenic peptides [61] . This search was motivated by a desire to minimize the therapeutic dosage, to produce the peptide synthetically rather than by using recombinant techniques, to help identify an orally active agent, and, quite simply, to generate new anti-angiogenic compounds. Several ap¬ proaches were used to achieve this goal: peptide dissection, phage-display, and peptide design. Presented below and listed in Table 2 are examples of some small anti-angiogenic peptides (<50 amino acids) identified using different approaches.
TSP-I peptides
An extremely potent inhibitor of angiogenesis is thrombospondin-1 (TSP-1), a large modular matrix protein containing three identical disulfide-linked 180 kD chains. TSP-1 is effective at subnanomolar concentra¬ tions, both in vitro and in vivo [62] [63] [64] and is secreted at high levels by a variety of normal cells. The use of intact TSP-1 as an anti-angiogenic drug in humans is, howev¬ er, not practical due to its size (450 kDa) and not Angiostatic proteins and peptides [20] ®The L-amino acid is substituted by the D-enantiomer.
desirable due to its diverse and multiple biological activities. For example, TSP-1 is involved in neurite outgrowth, platelet aggregation, as well as angiogenesis [65] , However, anti-angiogenic peptides derived from native TSP-1 could provide a reasonable alternative, A central 50-kDa proteolytic fragment of TSP-1 that contains its procollagen homology region and properdin type 1 repeats, retains all of the angiogenesis inhibitory activity of parent TSP-1 [63] , Moreover, TSP-1 repeats (about 60 residues each) have been extensively studied and are known to function as inhibitors of angiogenesis and glycosaminoglycan binding sites (reviewed in [66] ). Two peptides, residues 424-442 (Mai I) and residues 481-499 (Mai II) derived from these repeat domains, display anti-angiogenic activity through a CD36-dependent mechanism [63, 67] , However, micro-molar con¬ centrations of the peptides are required to achieve an effect equivalent to that produced by low nanomolar amounts of native TSP-1. This loss of activity could be recovered in one of the peptides, Mai II, by substituting an L-amino acid with its D-isoleucyl enantiomer. Activity was optimized by ethylamide-capping, which resulted in a similar potency to TSP-1 ethylamidecapped heptapeptide [65] , Following further modifica¬ tion to a nonamer containing the non-natural amino acid norvaline (see Table 2 ), this peptide successfully inhibited tumor growth [68] .
The crystal structure of the TSP-1 type 1 repeat [69] (see Figure 1C) contains a three-stranded, anti-parallel ^-sheet that consists of alternating stacked layers of tryptophan and arginine residues from respective strands, capped by disulfide bonds on each end. One face of the molecule has a positively charged groove that might be the 'recognition' domain for mediating inter¬ actions with various ligands. Peptides derived from these repeats also display )5-sheet character when examined by CD spectropolarimetry.
Tumstatin derivatives
As mentioned above, tumstatin (a3(IV)NCl) and its deletion mutant tum-5 (residues 54-132), possess antiangiogenic activity. To delineate the most active sequence within this 88 residue domain, smaller peptides were synthesized and screened for activity. Two peptides (Table 2 ): T3 (residues 69"88) and T7 (residues 74-98) were able to inhibit proliferation and to induce apop¬ tosis specifically in ECs. Similar to tumstatin and the tum-5 domain, these peptides bound to and functioned via integrin in an RGD-independent manner [70] , On a molar basis, peptide T3 was 2-to 5-fold less active than tumstatin or tum-5. Although both peptides have a propensity for j5-sheet formation, introduction of a disulfide bond between the two interstrand cysteines present in T3 did not improve activity, as predicted earher for parent tumstatin [70] .
Parathyroid hormone-related peptide Parathyroid hormone-related peptide (PTHrP) and the closely related parathyroid hormone (PTH) are peptide hormones that regulate serum calcium levels, vascular tone and bone formation [71] , PTHrP is composed of several domains with distinct physiological properties. The first 34 amino acids of PTHrP inhibit angiogenesis, and 5 of the first 10 amino acids in PTH and PTHrP are identical. Moreover, structure predictions indicate that these regions have similar conformations [71] . In human PTHi_34, residues 6-20 and 21-33 fold into two amphiphihe helices that form an overall twisted belt from the N-to the C-termini with the crossing point near residue Arg-20 [72] . The dimer interface is mainly hydrophobic and the mid-and C-terminal portions of the hydrophilic surface are composed primarily of positively charged residues. However, the sequence that promotes antiangiogenic activity seems to be the ten aperiodic N-terminal residues AVSEHQLLHD [71] , and this sequence is predicted to have a high propensity to form j?-sheet conformation, which may be 'locked-in' upon binding its receptor.
RGD-based peptides
The overexpression of adhesion molecules such as ayft, and j51-integrins, on ECs of angiogenic blood vessels is generally found to be associated with the angiogenesis process. This observation urged research¬ ers to develop antagonists that block EC interactions with the extracellular matrix as a way to inhibit angiogenesis [48, [73] [74] [75] [76] . One natural integrin-binding ligand is the RGD-tripeptide sequence present in nu¬ merous endogenous proteins.
Considerable research is being performed to identify other related sequences. One study using in vivo selection of phage display peptide libraries to isolate peptides that specifically home to angiogenic (tumor) blood vessels, revealed a number of peptide motifs that specifically bind to tumor vasculature. One of these peptides, RGD-4C {d(CDCRGDCFC)2} is a molecule containing the integrin-binding sequence RGD (Arg-Gly-Asp) ( Table 2) [21, 22, 77] . Another peptide, d(CNGRCVSG CAGRC)2, with a CX3CX3CX3 structural motif contains 6 the sequence NGR (Asn-Gly-Arg), known to be another cell adhesion binding motif (Table 2) . Phages expressing these peptides specifically home in on angiogenic blood vessels from different tumor types, including carcino¬ mas, sarcomas, melanomas. A third peptide contain¬ ing the motif GSL (Gly-Ser-Leu) is also frequently recovered from breast carcinoma and Karposi's sarco¬ ma [21] .
Flt-1 peptide
Vascular endothelial growth factor (VEGF) is a wellknown angiogenic stimulator, which functions through two endothelial specific tyrosine kinase receptors, Flt-1 (VEGFR-1) and Flk-1 (VEGFR-2). Tan et al. [78] demonstrated that an 11 amino acid peptide (Flt2-ll; Table 2 ) derived from the second immunoglobulin domain of Flt-1 functions as an angiogenesis inhibitor by inhibiting VEGF function through a non-VEGF binding mechanism, i.e., without binding to VEGF or inhibiting VEGF's binding to its receptors. Peptide sequences in Flt-1 were identified primarily using Flt-1 VEGF-binding domain data by mutational analysis [79] and the VEGF-Flt-1D2 protein crystal structure [80] . Of the two peptides chosen (SPNITVTLKKFPL and RPFVEMYSEIPE), the former one demonstrated antiangiogenic activity in the CAM assay, and this activity could be slightly enhanced by removing the N-terminal dipeptide SP.
The crystal structure of the VEGF-Flt-1D2 protein complex indicates that parts of this active peptide are within the third j?-sheet of Flt-1D2, and CD and NMR analyses indicate that the NITVTLKKFPL peptide (Flt2-11) in solution forms a stable extended structure, presumably ^-strand, that can be stabilized by self¬ association to a dimer at higher concentrations. In the context of a j9-strand conformation, the Flt-1 peptide NITVTLKKFPL would present N-terminal hydropho¬ bic amino acid residues I-V-L on the same face of the strand.
VEGF-binding peptides
Phage display has been used to identify peptides that bind to VEGF and thereby inhibit its angiogenic activity. By using this approach, Fairbrother et al. [81] identified a number of VEGF-binding peptides, and Pan et al. [82] reported the NMR structure of one of these peptides, a 19mer, that has a turn-helix conformation with hydrophobic residues partitioned to one face of the folded peptide and polar/charged residues at the other face. Binding to the VEGF dimer is promoted via interactions with hydrophobic residues.
Anginex
As discussed above, most anti-angiogenic agents are endogenous molecules or derived from endogenous molecules, primarily proteins. On the other hand, R,P.M. Dings et al.
Griffioen et al. [20] reported the potent anti-angiogenic activity of a designed peptide 33mer [83] , called anginex or ppcp-25. Anginex specifically targets angiogenically activated ECs, inhibiting EC adhesion to and migration on the extracellular matrix and thereby inducing apop¬ tosis. Although no specific receptor for anginex has yet been identified, it appears that one or more adhesion/ migration receptor(s), upregulated in angiogenically activated ECs, is (are) involved [20] . In tumor models in mice, anginex is highly effective at inhibiting tumor growth [84] [85] [86] .
NMR structural studies show that anginex folds amphipathically into a three-stranded anti-parallel Psheet motif [87] , The hydrophilic face of the folded peptide carries a high net positive charge (4-5), mostly from lysine residues. This fold and composition is similar to that found in a number of other j9-sheetstructured, anti-angiogenic cytokines, such as TNF [88] , lymphotoxin (LT or TNF-^ [89] , transforming growth factor-j9 (TGF-P) [90] , and bactericidal/permeability increasing protein (BPI) [91, 92] . The structure of BPI is shown in Figure ID to illustrate the extent of its Psheet fold. Although anginex contains a short j9-strand sequence identical to one from BPI, that same synthetic sequence from BPI demonstrates no anti-angiogenic activity, indicating that it is the imique anginex sequence and fold that impart anti-angiogenic function.
Structural similarities among anti-angiogenic proteins/peptides
Considering protein fragments and peptides discussed above, it should be apparent that aside from their functional commonality of being anti-angiogenic, these peptides, for the most part, are also structurally and compositionally similar. The vast majority folds as antiparallel p-shQQis and contain a relatively high incidence of hydrophobic and cationic residues.
In general, for smaller derived peptides (Table 2) , the same can be said. Because experimentally determined structures are not available for all these peptides, the program PSIPRED was used to assess folding potential. The secondary structures of all these smaller peptides are predicted to also exist in j?-strand conformation. Although these sequences are compositionally similar, sequence alignment analysis using several homology programs did not indicate significant sequential com¬ monalties among these peptides.
In addition, many other anti-angiogenic proteins, e.g. PF4 [93] , TNF [88] and BPI [91] , are also structurally and compositionally similar to protein fragments and smaller peptides discussed above. Although the signif¬ icance of this correlation is unclear, it appears that the mechanisms of action of these anti-angiogenics are not the same, i.e., they function using different receptors. Few receptors reported to mediate the signal leading to angiostasis are definitive. In fact, the picture in terms of receptors is quite untransparent and a number of these agents apparently can act on multiple receptors (see Table 1 ). For example, ATP-synthase on ECs has been reported to be a receptor for angiostatin [25] . However, other angiostatin receptors include and, to a lesser extent, ol^Pi [24] . Karumanchi et al. [94] demonstrated the existence of a low affinity cell surface glypican receptor for endostatin, along with a yet-to-be-identified high affinity receptor, and a third intercellular protein, an epitope (hTM3) in tropomyosin, was also found to bind endostatin [95] . Another such example is TSP-l, which requires, both in vitro [67] and in vivo [96] , the expression of the transmembrane receptor CD36 as the receptor for TSP-l. TSP-l is also known to bind to other receptors, such as Syndecan, heparin sulfate proteogly¬ cans (HSPG) and integrin associate protein (lAP) (reviewed in [66] ). The presence of multiple receptors, although possibly being therapeutically beneficial, com¬ plicates our understanding of tumor angiogenesis and our ability to develop receptor-specific antagonists.
The compositional and structural similarity noted among these anti-angiogenic peptides may be used, possibly via combinatorial approaches, to design addi¬ tional therapeutic anti-angiogenic agents. In the context of a j^-strand conformation, for example, the Flt-1 peptide NITVTLKKFPL would present N-terminal hydrophobic amino acid residues I-V-L on the same face of the strand. This presentation pattern is observed in a number of anti-angiogenic peptides. In fact, anginex shows the same )?-strand I-V-L pattern, as well as the cross-strand pattern, V-M-L. Because anginex, for example, forms j5-sheet structure and can be used as a presentation scaffold, it might be possible to vary a set number of residues and make analogs having various permutations and combinations of amino acid residues. In this way, one might optimize angiostatic potential. In addition, it might be possible to reduce the size of the active peptide, which could help lead to the design of an actual small molecule mimetic of an anti-angiogenic peptide.
Conclusions
As more anti-angiogenic peptides are identified, it is becoming apparent that there are compositional and structural similarities that may well act to convey bioactivity. These peptides have a high incidence of hydrophobic residues, are primarily cationic in nature and fold as anti-parallel p-sh&Qts. Aside from the fact that small peptide inhibitors have various advantages over larger anti-angiogenic agents, they may also be used to help design better, more active anti-angiogenic peptides or even small molecule mimetics.
Based o« structure-actMly relationships of the angiostatie B-sheet-forming pepHde angines, w have designed a mtoetic, 6DBF7, which inhibits angiogenesis and tnmor growth in mice. 6DBr7 is composed of a B^iheet-indncing dibenzofnran (DBF) tnmmimetic and two short key amino acid seqnences from anginev. This novel antiangiogenic molecnle n. more effective in vivo than parent anginex. In a monse xenograft model for ovarian carcinoma, 6DBF7 is observed to rednce tnmor growth by np to 80%. It is snggested that the activity is based on antiangiogenesis because in vitro tube formation is inhibited and becanse treatment of tnmor-bearing mice led to a significant rednction in microvessei density within the tnmor. This partial peptide-mimetic is the first EC-specific molecuie designed as a snbstitnte for an angiostatie inhibitor' peptide.
Angiogenesis, the process of new blood vessel formation, is key to normal organ development, as well as to various pathological disorders like cancer, arthritis, diabetic ' opathy and restenosis (1) . The use of agents that can inhibit angiogenesis, particularly in anti-tumor research e.g. (2,3) , has indicated that antiangiogenic therapy can be a promising therapeutic modaihy in the future. To date, the search for angiogenesis inhibitor has been ocused on controlling two of the processes that promote angiogenesis: endothelial cell (EC)* growth and EC adhesion (4, 5) . Targeting EC as anti-tumor treatment is attractive primarily because EC are more accessible than are other cells to pharmacologic agents delivered via the blood, and EC are genetically stable and are not easily mutated into drug msistant variants Most antiangiogenic agents have been discovered by identifying endogenous molecules, primarily proteins, that inhibit EC growth. This traditional approach has produced a number of antiangiogenics, such as platelet factor-4 (PF4) (6), thrombospondin (7), interfen>n-y inducible protein-10 (8). angiostatin (9), endostatin and restin (2,10) and bactericidal-permeability increasing (BPI) protein (11) .
Numerous angiostatie compounds have been identified, many of which are currently in various phases of clinical cancer trials (http7/cancertrials.nci.nih.gov). Although a number of compounds have shown promise in the clinic, no major breakthroughs have been reported using antiangiogenic agents as stand-alone therapy. This underscores the need for more and better angiostatie compounds for use as stand-alone or in combination with conventional therapies.
Moreover, some angiogenesis inhibitors have been shown to be ineffective or to cause diverse 2 and multiple unwanted biological side-effects (12) . This latter phenomemon was, to some extent, expected as many of these endogenous angiostatic proteins are pleiotropic, i.e., they are involved in several biological processes. Often these functions are found to arise from separate sites on the molecule and thus can be separated using smaller segments or domains of a given protein (13) . This relates to the search for new antiangiogenic agents, which is aimed at improving specificity, reducing the therapeutic dosage, and minimizing molecular size with a small molecule antiangiogenic agent or antiangiogenic protein mimetic. This is one of the main goals among structural biologists and pharmaceutical chemists working to produce novel antiangiogenic agents. For the design of small molecule mimetics of antiangiogenic proteins, the identification of specific, functionally key amino acid residues and their spatial relationships is crucial. Nevertheless, structure-activity relationships (SARs) for antiangiogenic proteins are sorely needed, and even the analysis of high-resolution molecular structures of a number of antiangiogenic proteins, e.g., endostatin (14) , PF4 (15) and BPI (16) , has yet to provide this information.
Recently, we reported the design of the anginex peptide, a cytokine-like B-sheet-forming peptide 33mer (17) , which is a potent inhibitor of angiogenesis (1) and tumor growth (18) (19) (20) .
Anginex is more effective at inhibiting EC growth than platelet factor-4 and several other wellknown angiogenesis inhibitors such as angiostatin, endostatin, AGM-1470 and thrombospondin-1 (1) . This peptide 33mer acts by specifically blocking adhesion and migration of angiogenically-activated EC, leading to apoptosis and ultimately to inhibition of angiogenesis in vitro and in vivo and inhibition of human tumor growth by up to about 80% in various models (18) (19) (20) . Anginex is an amphipathic B-sheet-forming peptide (17, 21) , and because of anginex's relatively small size, a complete SAR is easier to perform than with larger known antiangiogenic proteins like those mentioned above. Here, we report for the first time the design of a partialpeptide mimetic of anginex that was based on the identification of functionally key residues and the conformation responsible for anginex's antiangiogenic activity. were carried out on an ABI (Applied Biosystems, Inc.) 431 peptide synthesizer using Fmoc methodology and BOP/HOBT as coupling reagents. Fmoc-DBF-C02H (1) was prepared by slight modification of the reported method (22) . In this nine-step synthesis, the intermediates and final product were characterized by TLC and *H NMR, with GC-LRMS, '^C NMR, mp, and IR being used as appropriate. Coupling of 1 to 120 as well as of LI 1 to the peptide-DBF-NH2 was performed on the synthesizer. Coupling of Fmoc-K10-CO2H to the peptide-DBF-Ll I-NH2 sequence was difficult and required manual SPPS using the more reactive HATH reagent (23).
The remaining couplings required for production of 2DBF7 through 11DBF7 were carried out using BOP/HOBT conditions on the peptide synthesizer. After the final Fmoc deprotection, each of the DBF peptides was released from the resin with simultaneous removal of all acidolyzable trityl and tert-h\iXy\ side-chain protecting groups using Reagent K (24). A Rink amide or similar resin was used to provide the primary amide form of the C-terminal D24 unit. Lyophilized crude peptides were purified by HPLC as described above. Purity and composition of the peptides were verified by analytical HPLC, matrix assisted laser desorption ionization (MALDI) mass spectrometry using a Hewlett-Packard G2025A system and sinapinic acid as matrix, and analysis of amino acid composition of hydrolysates (6N HCl, 110 °C, 24 h, under argon).
NMR spectroscopy^-For NMR measurements, freeze-dried DBF analogs were dissolved in water-DMSO-DPC mixture. Peptide concentration was 3 mM. pH was adjusted to pH 5.7 by adding pL quantities of NaOD or HCl to the peptide sample. NMR spectra were acquired on a Varian UNITY Plus-600 NMR spectrometer at 25 °C.
2D-homonuclear TOCSY with DIPSI (25) spinlock (mixing time 80 ms) was used to identify spin systems. 2D NOESY experiments (26) were performed for sequential assignments and conformational analysis. WATERGATE (27, 28) was used to attenuate the water resonance.
Spectra were collected as 256 to 512 tl experiments, each with 2048 complex data points over a spectral width of 6 kHz in both dimensions with the carrier placed on the water resonance. 16 scans were time averaged per tl experiment. Data were processed directly on the spectrometer using VNMR (Varian, Inc., Palo Alto) or NMRPipe (29) on an SGI workstation.
Structural modeling-Analysis of NOE growth curves indicated that backbone to backbone mter-proton NOEs were normally maximum at about 200 ms. Interproton distance constraints were derived from NOEs assigned in 'H NOESY spectra acquired with mixing times of 100 ms.
NOEs were classified as strong, medium, weak or very weak corresponding to upper bound distance constraints of 2.3,2.8, 3.5, and 4.5 A, respectively. The lower bound restraint between non-bonded protons was set to 1.8 A. Pseudo-atom corrections were added to the upper bound distance constraints where appropriate, and a 0.5 A correction was added to the upper bound for NOEs mvolving methyl protons. Hydrogen bond constraints were identified from the pattern of sequential and interstrand NOEs involving NH and QH protons, together with evidence of slow amide proton-solvent exchange. Each hydrogen bond identified was defined using two distance constraints; = 1.8 to 2.5 A, and rn-o = 1.8 to 2.5 A.
Derived intemuclear distance constraints were used in calculating structures for 6DBF7 by using X-PLOR (30) . The molecule was created and a template coordinate set was generated by using the Template routine. The ab initio simulated annealing (SA) protocol was then used. The SA procedure ran high temperature dynamics (3000 K for 120 ps) and then cooled down to 100 K in 50 K steps with 1.5 ps molecular dynamics at each step. Powell minimization was performed at 100 K for 1000 steps. Structure refinement was done based on simulated annealing starting at 1000 K and ending at 100 K. Final structures were subjected to the X-PLOR Accept In vitro angiogenesis assay-Sprouting and tube formation of bovine EC (BCE) were studied using cytodex-3 beads overgrown with BCE in a 3-dimensional collagen gel (vitrogen-100.
Collagen Corp., Fremont, CA, USA) as described by van der Schaft et al (31) . Following gelation, culture medium containing 20 ng/mL bFGF, with or without anginex or DBF analogs, was applied on top of the gel. After 24 hours of cell culture at 37 °C, photographs were made as 6 shown in the figure. The amount of sprouting in each well (i.e. the total length of the sprouts) was quantified by the computer program NIH image. To quantify differences in sprouting and tube formation, statistical analysis was performed using the Mann-Whitney U test.
Tumor model studies in athymic (nude) mice-In all studies, female athymic nude mice (nu/nu, 5-6 weeks old) were used. These mice were purchased from the National Cancer Institute and allowed to acclimatize to local conditions for at least one week. Animals were given water and standard chow ad libitum, and were kept on a 12 hour light/dark cycle. All experiments were approved by the University of Minnesota Research Animal Resources ethical committee. Mice were randomized and split into three groups: 1) human serum albumin (10 mg/kg/day), 2) anginex (10 mg/kg/day) and 3) DBF analog (10 mg/kg/day). Compounds were diluted m 100 mM SDS and administered using osmotic mini-pumps (Durect, Cupertino, CA). To assess the extent of total cell apoptosis, tissue sections were stained by using the TUNEL (terminal deoxyribonucleotidyl transferase-mediated dUTP-nick-end labeling) assay, which was performed according to the manufacturer's instructions {in situ cell death detection kit, fluorescem; TUNEL, Roche). Digital images were stored and processed using Adobe Photoshop (Adobe Inc., Mountain View CA). Quantification of microvessel density, the rate of proliferation and total cell apoptosis were determined as described earlier (32) . Statistical analysis was performed using the Student's t-test.
Toxicity assays-As an indirect measurement of general toxicity, body weights of mice were monitored twice weekly, using a digital balance (Ohaus Florham, NJ). To determine hematocrit and creatinine levels, blood samples were extracted by tail vein bleedings one day after terminating treatment and blood was collected in heparinized micro-hematocrit capillary tubes (Fisher; Pittsburgh, PA). For hematocrit levels, samples were spun down for 10 minutes in a micro-hematocrit centrifuge (Clay-Adams; NY), and the amount of hematocrit was determined using an international microcapillary reader (ffiC; Needham, Mass). To obtain creatinine levels, a kit was purchased from Sigma (Sigma Diagnostics; St Louis, MO) and used according to the manufacturer's instructions.
RESULTS
Design of a partial-peptide mimetic-^For input into designing the mimetic, we first performed structure-activity studies on anginex. Working with this relatively small peptide 33mer allowed for a thorough assessment of functionally-key residues by using alanine scanning and walk-through variants. The relative anti-proliferative effect of alanine-substituted analogs of anginex against EC is plotted in Figure \A . Residues that demonstrate the most significant drop in the ability of anginex to inhibit EC proliferation are hydrophobic residues within the first two B-strands: 13, L5, V7, LI 1 and 120. Conformationally, these functionally key hydrophobic residues all lie on the same face of the amphipathic anti-parallel 6-sheet (17, 21) . Also shown in Figure lA are anti-proliferation activities of eight walk-through dodecapeptides that successively sample segments of the anginex sequence, shifting three residues in each peptide. Only three walk-through peptides (IC50 values listed at the right) demonstrate any significant anti¬ proliferative activity relative to parent anginex. As with results from alanine scanning, these peptides also encompass 6-strands 1 and 2. Based on these results, we concluded that antiangiogenic activity is localized within 6-strands 1 and 2 and that residues in turns 1 and 2 and 6-strand 3 are functionally dispensable. For orientation, the 6-strand alignment for anginex is depicted in Figure IR ; portions of the molecule containing the key sequences are boxed.
Using this information, we designed the DBF-series of partial-peptide mimetics, in which 6-strand 3 and turn 2 of anginex were omitted and a dibenzofuran (DBF) 6-turn mimetic (33, 34) was used in place of turn 1 and residues F12, K13 and W18, K19 of 6-strands 1 and 2, respectively. The DBF 6-tum mimetic was used in order to maintain the bioactive 6-sheet conformation of anginex (21) . The parent DBF-based compound depicted in Figure 1C is called 11DBF7, where numbers at the left and right of DBF refer to the number of amino acid residues 9 in the N-and C-terminal strands, respectively, from anginex. To identify the shortest sequences required for bioactivity, a series of N-and C-terminal deletion variants of 11DBF7 was made as listed in Table I. fi-sheet structure is preserved in DBF analogs-used NMR spectroscopy to investigate whether 6-sheet conformation was preserved in DBF analogs. Analogs 11DBF7 and 6DBF7 (that has more equivalent 6-strand lengths) were the focus of this structural study. Due to their limited water solubility and the desire to mimic a membrane-like environment, these compounds were investigated in dodecylphosphocholine (DPC) micelles. At the millimolar concentrations required for NMR work, 11DBF7 gave overlapping resonances that made spectral analysis ambiguous, whereas 6DBF7 gave excellent NMR spectra that allowed complete structure analysis. NOEs and coupling constants diagnostic of anti-parallel 6-sheet conformation were readily identified and used in computational modeling. The superimposed 28 lowest energy structures ( Fig. 2A) have a backbone RMSD value (N-and C-terminal residues excluded) of 0.11 A. Additional structural statistics are given in Table II . A simplified illustration of this folding pattern is shovra in Figure 2B , which highlights residues on both hydrophobic and hydrophilic surfaces of the 6-sheet. In this orientation of the molecule, the dibenzofuran moiety is lying on edge. Notice also that two aliphatic hydrophobic residues leucine (LI 1) and isoleucine (120) from anginex are packed against the phenyls of the DBF group in 6DBF7 (Fig. 2B) . In effect, this sets up and helps to stabilize the 6-sheet fold (22) . Based on this structural information, we concluded that other DBF analogs would fold similarly, albeit to various extents depending on the lengths of the two strands, i.e., strands of equal length are expected to be better able to form 6-sheets. DBF analogs retain antiangiogenic activity-In endothelial cell (EC) proliferation assays, we demonstrated that 11DBF7, as well as a number of shorter analogs, including 6DBF7, are effective at inhibiting EC groAvth. Exemplary dose response curves for all xDBF7 analogs are given in Figure ' iA, and IC50 values for all analogs are listed in Table I . Even though DBF analogs are less active than parent anginex, this may be explained in part by their having a decreased number of residues. Some of the analogs are missing residues identified by alanine scanning as being functionally important (e.g., L5 and 13). Nonetheless, a number of these shorter analogs remain reasonably active, and it appears that the N-terminal hexapeptide SVQMKL and C-terminal hexapeptide IIVKLN are most essential for maintaining antiangiogenic activity.
Angiostatic potential was further demonstrated in the collagen gel-based sprout formation assay (21) . Whereas control cultures show numerous sprouts (Fig. 3B) , treatment with 6DBF7 (Fig. 3C), 11DBF7 (Fig. 3D) and anginex (Fig. 3£ ) all demonstrate highly reduced sprouting.
These effects are quantified in Table 1 . In general, reducing the number of amino acid residues in the B-strands leads to reduced inhibition of sprout formation, comparable with results from the EC proliferation assay. Nonetheless, some analogs were active in this assay and one of the shortest analogs, 6DBF7, did demonstrate a significant inhibitory effect on tube formation. The kinetics of inhibition using DBF analogs, moreover, were the same as those observed with parent anginex (data not shown). (Fig. 4A) .
In further experiments, we initiated treatment seven days after inoculation with tumor cells to allow establishment of tumors prior to the start of treatment. Using this protocol, anginex and 11
were found to inhibit tumor growth by up to 70% during the course of treatment (Fig.   4B ). At the end of the four week administration period (day 35), the rate of tumor growth began to increase, but remained at about 50% ten days post-treatment (not shown) when animals were sacrificed for analysis of tumor tissue. Interestingly, the smaller analog, 6DBF7, was even more effective than anginex or 11DBF7 at inhibiting the growth of tumors (Fig. 4B) . The reason for this is unclear, but may be related to improved bioavailability of 6DBF7. (Fig. 4C) , was significantly reduced by treatment with anginex (Fig. 4D) , F7 (Fig. 4E) or 6DBF7 (Fig. 4F ). These antiangiogenic compounds had a significant effect as well on vessel architecture, demonstrating a dmp in the number of end points, branch points and vessel length (Table III) . In addition, antiangiogenic treatment also mduced the mte of proliferation of tumor cells as determined by immunohistochemical staining of PCNA in co-osections of tumors ( Table Iff) . As a result of angiogenic inhibition, the number of apoptotic tumor cells mcreased from 31U103 in the control, to 620± 146 and 851 ± 162 in anginex and 6DBF7 treated animals, respectively.
In all in vivo experiments, treatment with anginex, 11DBF7 and 6DBF7 did not show any sign of toxicity as assessed by unaltered behavior and normal weight gain during experiments (see inserts to Fig. 4A, B) . Moreover, hematocrit and creatinine levels in treated animals were normal relative to control, indicating the absence of toxicity to bone marrow and kidney, respectively. Upon autopsy, macro-and microscopic morphology of internal organs were also observed to be normal within all experimental groups of animals.
DISCUSSION
Here, we identified functionally key amino acid residues in the B-sheet-forming anginex peptide that promote its angiostatic activity and using this SAR infonnation, designed partial non-peptidic B-sheet mimetics of anginex. Members of this novel class of DBF-based compounds ate effective antiangiogenic agents both in vitro and in vivo. Moreover, the in vivo anti-tumor activity of one of these DBF mimetics, 6DBF7, is improved over that of the larger parent molecule anginex.
The fi-sheet conformation in particular is crucial to the antiangiogenic activity of these DBF analogs, just as it is for parent anginex peptide (17, 21) . 6DBF7 is shown here to fold as an amphipathic B-sheet, with functionally key hydrophobic residues lying on the same face of the molecule. Interestingly, the crystal structure of VEOF complexed with an anti,ngi"c"ipeptide (Flt-1D2) (35) derived from one of its endothelial cell-specific tyrosine kinare receptors 12 Flt-1, indicates that functionally key segments of Flt-1D2 are located wHhin its B-sheet domain.
Moreover, one of the peptides derived from this domain, NITVTLKKFPL, inhibits angiogenesis through a non-VEGF binding mechanism, i.e., without binding to VEGF or inhibiting VEGF's binding to Its receptois (36) . CD and NMR analyses indicate that this Fit-1 peptide 1 Imer forms a stabie extended B-strand structure in solution. In this conformation, the peptide would present N-terminal hydrophobic amino acid residues I-V-L on the same face of the strand. This I-V-L presentation pattern is also present in 6DBF7 (6-strand 2), aiong with the cross-strand hydrophobic pattern V-M-L (6-strand 1). Aithough the efficacy of the Flt-1 peptide is much less than that of 6DBF7, this structural/compositional simiiarity between these two peptides suggests that on the molecular level, the 6-sheet structure of these molecules is pivotal to their activity (37) which may suggest signaling through a common cellular receptor.
Many other antiangiogenic proteins whose high-resolution molecular structures are known e.gs., endostatin (14) . FF4 (15), ThiF-a (38), BPI (16) , and TSP-1 type 1 repeat (39) . are also ' structurally (antiparallel 6-sheet) and compositionally (high incidence of hydrophobic and with a yet-to-be-identified high affinity receptor (42) and an intercellular epitope (hTM3) in tropomyosin (43) . And for another well-known antiangiogenic protein, TSP-1, there are four identified receptors: syndecan. heparin sul&te proteoglycans (HSPG), integrin-associated protein (lAP) (reviewed in (12)) and its long-known transmembrane receptor CD36 (44, 45) .
Even with these unceifainities, the compositional and structural similarity noted among anginex, 6DBF7 and various antiangiogenic proteins and peptides may be used to further improve or optimfae the efficacy of anginex peptide mimetics and in the design of additional novel thetapeutic antiangiogenic agents. For the present. 6DBF7 appears to be one of the most potent antiangiogenic and antitumor agents known. This claim is supported by the observation 13 that angmex is as potent as angiostatin and more potent than endostatin at inhibiting the growth of ovarian tumors in mice (18) . Therefore, based on the present comparison with anginex, 6DBF7 must also be more potent in vivo than endostatin or angiostatin. The design of 6DBF7 places us on the road to creating an actual small molecule pharmaceutical agent that could be used as an effective therapeutic against cancer, as well as against other angiogenically-related pathologic disorders like arthritis, restenosis, endometriosis and diabetic retinopathy. "After binarization of the images of the PCNA-staining, proliferation was estimated by scoring the total number of white pixels per field.
"After binarization of the images of the CDS 1-staining, microvessel density was estimated by scoring the total number of white pixels per field.
Mean number of vessel end points as determined after skeletonization of the images (32) .
Mean number of vessel branch points/nodes per image.
"Mean total vessel length per image.
All results are expressed as mean pixel counts per image (± standard error).
Figure legends 
